Exagen Maintains 2026 Revenue Outlook at $72 Million to $75 Million

John Kim

1 min read

Add as a preferred source on Google

Exagen Maintains 2026 Revenue Outlook at $72 Million to $75 Million

Its myositis offering remains on track for an early 2027 launch.

By John Kim

Published Nov 11, 2026, 1:30 PM EST

A clinical sample vial stands between two clear glass markers / TokenPost.ai

Exagen Inc. maintained its full-year 2026 revenue outlook at $72 million to $75 million, while its myositis offering remains on track for an early 2027 launch.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.